Skip to main content
Premium Trial:

Request an Annual Quote

Biodesix Raises $12M in Series D Extension

NEW YORK (GenomeWeb News) – Biodesix today announced the closing of a $12 million extension of its Series D financing round.

The funds will support commercialization of its VeriStrat blood-based test for non-small cell lung cancer, as well as clinical validation studies, product development, and ongoing collaborations with biotechnology and pharmaceutical companies.

The Boulder-based molecular diagnostic firm closed on the Series D round in July 2011, raising $20 million. Biodesix said it plans to pursue clearance from the US Food and Drug Administration for VeriStrat, a mass spectrometry-based test performed out of the company's CLIA laboratory to help guide physicians treating patients with NSCLC.

The Scan

Lung Cancer Response to Checkpoint Inhibitors Reflected in Circulating Tumor DNA

In non-small cell lung cancer patients, researchers find in JCO Precision Oncology that survival benefits after immune checkpoint blockade coincide with a dip in ctDNA levels.

Study Reviews Family, Provider Responses to Rapid Whole-Genome Sequencing Follow-up

Investigators identified in the European Journal of Human Genetics variable follow-up practices after rapid whole-genome sequencing.

BMI-Related Variants Show Age-Related Stability in UK Biobank Participants

Researchers followed body mass index variant stability with genomic structural equation modeling and genome-wide association studies of 40- to 72-year olds in PLOS Genetics.

Genome Sequences Reveal Range Mutations in Induced Pluripotent Stem Cells

Researchers in Nature Genetics detect somatic mutation variation across iPSCs generated from blood or skin fibroblast cell sources, along with selection for BCOR gene mutations.